Bio-Rad Laboratories Inc (BIO) - Total Liabilities
Based on the latest financial reports, Bio-Rad Laboratories Inc (BIO) has total liabilities worth $2.94 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Bio-Rad Laboratories Inc to track the company's year-over-year net asset growth rate.
Bio-Rad Laboratories Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Bio-Rad Laboratories Inc's total liabilities have evolved over time, based on quarterly financial data. See BIO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Bio-Rad Laboratories Inc Competitors by Total Liabilities
The table below lists competitors of Bio-Rad Laboratories Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Enpro Industries
NYSE:NPO
|
USA | $1.07 Billion |
|
Cpi Property Group SA
XETRA:O5G
|
Germany | €12.70 Billion |
|
Linde India Limited
NSE:LINDEINDIA
|
India | Rs15.42 Billion |
|
AutoNation Inc
NYSE:AN
|
USA | $12.40 Billion |
|
Samsung Engineering
KO:028050
|
Korea | ₩5.59 Trillion |
|
Getinge AB ser. B
ST:GETI-B
|
Sweden | Skr26.98 Billion |
|
Open Text Corp
TO:OTEX
|
Canada | CA$9.52 Billion |
|
GDS Holdings Limited
F:G40
|
Germany | €52.26 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Bio-Rad Laboratories Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bio-Rad Laboratories Inc (BIO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio-Rad Laboratories Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio-Rad Laboratories Inc (1985–2025)
The table below shows the annual total liabilities of Bio-Rad Laboratories Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.12 Billion | +11.74% |
| 2024-12-31 | $2.79 Billion | -21.45% |
| 2023-12-31 | $3.56 Billion | -8.45% |
| 2022-12-31 | $3.89 Billion | -5.54% |
| 2021-12-31 | $4.11 Billion | +33.03% |
| 2020-12-31 | $3.09 Billion | +37.22% |
| 2019-12-31 | $2.25 Billion | +41.68% |
| 2018-12-31 | $1.59 Billion | +18.47% |
| 2017-12-31 | $1.34 Billion | +5.62% |
| 2016-12-31 | $1.27 Billion | +4.28% |
| 2015-12-31 | $1.22 Billion | +5.46% |
| 2014-12-31 | $1.16 Billion | -3.82% |
| 2013-12-31 | $1.20 Billion | -15.82% |
| 2012-12-31 | $1.43 Billion | +5.59% |
| 2011-12-31 | $1.35 Billion | -11.16% |
| 2010-12-31 | $1.52 Billion | +21.14% |
| 2009-12-31 | $1.26 Billion | +30.00% |
| 2008-12-31 | $966.62 Million | -3.33% |
| 2007-12-31 | $999.90 Million | +28.75% |
| 2006-12-31 | $776.63 Million | +1.04% |
| 2005-12-31 | $768.61 Million | -0.79% |
| 2004-12-31 | $774.73 Million | +55.95% |
| 2003-12-31 | $496.79 Million | +47.15% |
| 2002-12-31 | $337.62 Million | -15.63% |
| 2001-12-31 | $400.15 Million | -0.38% |
| 2000-12-31 | $401.66 Million | -10.50% |
| 1999-12-31 | $448.80 Million | +193.33% |
| 1998-12-31 | $153.00 Million | -1.42% |
| 1997-12-31 | $155.20 Million | +53.06% |
| 1996-12-31 | $101.40 Million | -20.78% |
| 1995-12-31 | $128.00 Million | -4.41% |
| 1994-12-31 | $133.90 Million | -10.49% |
| 1993-12-31 | $149.60 Million | -9.66% |
| 1992-12-31 | $165.60 Million | +2.03% |
| 1991-12-31 | $162.30 Million | +22.86% |
| 1990-12-31 | $132.10 Million | +14.37% |
| 1989-12-31 | $115.50 Million | +20.56% |
| 1988-12-31 | $95.80 Million | +16.97% |
| 1987-12-31 | $81.90 Million | +40.48% |
| 1986-12-31 | $58.30 Million | +40.14% |
| 1985-12-31 | $41.60 Million | -- |
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, pu… Read more